Show simple item record

Authordc.contributor.authorGonzález Hormazábal, Patricio 
Authordc.contributor.authorGutiérrez Enriquez, Sara es_CL
Authordc.contributor.authorGaete, Daniel es_CL
Authordc.contributor.authorReyes, José M. es_CL
Authordc.contributor.authorPeralta Musre, Octavio es_CL
Authordc.contributor.authorWaugh, Enrique es_CL
Authordc.contributor.authorGómez, Fernando es_CL
Authordc.contributor.authorMargarit, Sonia es_CL
Authordc.contributor.authorBravo, Teresa es_CL
Authordc.contributor.authorBlanco Castillo, Rafael es_CL
Authordc.contributor.authorDiez, Orland es_CL
Authordc.contributor.authorJara Sosa, Lilian es_CL
Admission datedc.date.accessioned2011-06-14T19:44:15Z
Available datedc.date.available2011-06-14T19:44:15Z
Publication datedc.date.issued2011-04
Cita de ítemdc.identifier.citationBREAST CANCER RESEARCH AND TREATMENT Volume: 126 Issue: 3 Pages: 705-716 Published: APR 2011es_CL
Identifierdc.identifier.issn0167-6806
Identifierdc.identifier.otherDOI: 10.1007/s10549-010-1170-y
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/128806
General notedc.descriptionArtículo de publicación ISIes_CL
Abstractdc.description.abstractThe distribution of BRCA1/2 germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of BRCA1/2, and these included a low number of BC and/or OC patients. Moreover, the prevalence of BRCA1/2 genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. To determine the contribution of BRCA1/2 LGRs in Chilean BC patients, we analyzed 56 high-risk subjects with no pathogenic BRCA1/2 point mutations. Germline BRCA1/2 point mutations were found in 23 (7.1%) of the 326 Chilean families. Families which had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). We identified 14 point pathogenic mutations. Three recurrent mutations in BRCA1 (c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in BRCA2 (c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. Taken together BRCA1/2 recurrent point mutations account for 65.2% (15/23) of the BRCA1/2 (+) families. No large deletions or duplications involving BRCA1/2 were identified in a subgroup of 56 index cases negative for BRCA1/2 point mutations. Our study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of BRCA1/2 mutations and allelic variants.es_CL
Patrocinadordc.description.sponsorshipVicerrectoria de Investigacion y Desarrollo (VID) Universidad de Chile ENL 10/04 Corporacion Nacional del Cancer (CONAC) UICC ICR/08/152 National Cancer Institute, National Institutes of Health NO2-CO-41101 Spanish Health Ministry FIS 05/2181es_CL
Lenguagedc.language.isoenes_CL
Publisherdc.publisherSPRINGERes_CL
Keywordsdc.subjectBreast canceres_CL
Títulodc.titleSpectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean familieses_CL
Document typedc.typeArtículo de revista


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record